Compare BHRB & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | SGP |
|---|---|---|
| Founded | 1852 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.8M | 932.9M |
| IPO Year | 2023 | N/A |
| Metric | BHRB | SGP |
|---|---|---|
| Price | $63.12 | $22.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $71.80 | $45.00 |
| AVG Volume (30 Days) | ★ 111.3K | 50.8K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.62 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | $34.53 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.45 | $20.15 |
| 52 Week High | $70.90 | $30.56 |
| Indicator | BHRB | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 38.56 |
| Support Level | $61.19 | $20.95 |
| Resistance Level | $67.47 | $26.29 |
| Average True Range (ATR) | 1.25 | 1.48 |
| MACD | -0.10 | -0.26 |
| Stochastic Oscillator | 53.96 | 11.65 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.